Pharma giants challenge French regulator over obesity drug ad penalties
Two pharma companies contest French regulator sanctions over obesity drug advertising compliance.
Event / Health
GLP-1 Medication Advertising Sanctions
French medicines agency ANSM issued financial sanctions against Novo Nordisk France and Eli Lilly France for direct-to-consumer advertising campaigns promoting obesity medications in violation of prescription drug advertising regulations.
1 reported locations
Daily activity
0 articles0 articles
2026-08-18 to 2026-11-15 · UTC publication dates
Coverage begins 4 May, 12:07 UTC
Follow the documented timeline or explore the related reporting.
What happened
ANSM cites concern about misleading messaging in obesity medication context
The ANSM stated that the advertising campaigns were susceptible to misleading the public in a context marked by significant media coverage and increasing misuse of GLP-1 analogs for aesthetic weight loss purposes rather than medical obesity treatment. The agency aims to prevent communications that valorize medication treatment as the primary response to obesity.
ANSM sanctions Novo Nordisk France with 1.78 million euros for obesity drug advertising
The French national medicines agency (ANSM) announced on May 4 that it imposed a financial sanction of 1.78 million euros against Novo Nordisk France for unauthorized advertising campaigns promoting obesity treatments. The breakdown includes 1 million euros for advertising Saxenda and 783,838 euros for Wegovy, both prescription medications for obesity management.
ANSM determines advertising campaigns constituted indirect promotion of prescription medicines
The ANSM determined that the obesity-related advertising campaigns from Novo Nordisk and Eli Lilly constituted indirect promotion of prescription medications that are subject to mandatory medical supervision. French regulations prohibit any public advertising for these treatments. The campaigns were widely distributed through public channels including billboards, public transportation, press, and social media.
Novo Nordisk France contests ANSM sanction and considers legal recourse
In response to the ANSM sanction, Novo Nordisk France stated that it firmly contests the position of the ANSM and is examining potential legal avenues to appeal the decision.
ANSM sanctions Eli Lilly France with 108,766 euros for Mounjaro advertising
The French national medicines agency (ANSM) sanctioned Eli Lilly France with 108,766 euros for a public awareness campaign promoting Mounjaro, an obesity treatment medication, in violation of regulations prohibiting direct-to-consumer advertising of prescription medications.
Eli Lilly France defends obesity awareness campaign as compliant with regulations
Eli Lilly France acknowledged the ANSM decision and defended its April 2025 awareness campaign titled 'Obesity, that's a sick thing' as conforming to applicable regulations governing communications relating to human health.
Read the coverage
2 alternative perspectives
French regulators penalize pharma giants for obesity drug advertising
French regulators fined Novo Nordisk and Eli Lilly for unauthorized obesity drug advertising campaigns.